0001493152-26-022629
SEC filingTharimmune reported significantly wider Q1 2026 losses of -$36.9M operating and -$47.3M net income versus prior year, driven by expanded digital asset treasury strategy and increased G&A expenses, though diluted EPS improved to -$0.23 from -$0.99.
Tharimmune, Inc. (CNTN) reported substantial increases in losses for the first quarter of fiscal 2026 ended March 31, 2026, primarily due to its strategic shift toward a digital asset treasury approach. Operating income deteriorated to -$36.9 million from -$2.5 million in Q1 2025, a -1347.7% change, as the company ramped up general and administrative expenses to support this pivot and ongoing research and development of product candidates. Management notes expectations for continued G&A growth tied to personnel expansion for the digital asset strategy, which began gaining traction with a November 2025 private placement that strengthened liquidity.
Net income widened to -$47.3 million from -$2.5 million year-over-year (-1762.7%), incorporating the operating shortfall alongside other factors. Despite the headline losses, diluted EPS showed improvement to -$0.23 from -$0.99, a 76.8% positive shift, reflecting the impact of share count changes from recent capital raises. This per-share progress highlights how financing activities mitigated some dilution effects amid aggressive expense growth.
Looking forward, the company anticipates rising G&A expenses as headcount grows to execute the digital asset treasury strategy alongside product development. This positions Tharimmune to navigate volatility in that asset class while pursuing biotech innovation, with forward-looking statements flagged by terms like 'expects' and 'plans' per filing disclosures.